Press Releases
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel…
Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…
Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an…
FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors…
EMA grants Orphan Drug Designation to Debiopharm International SA’s FGFR inhibitor Debio 1347 in the treatment of biliary tract cancer
Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284
Debiopharm International SA announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective…
Debiopharm Group™ moves forward three of its oncology clinical programs and will present the recent progresses at the 50th American…
Debiopharm Group™ initiates phase I dose escalation study with Debio 1347 (CH5183284) in advanced solid tumors with FGFR alterations